SequelSEC

NextCure, Inc. NXTC

Pharmaceutical Preparations · CIK 0001661059 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2020-12-31
Operating income
-$16.24M
Fiscal year ended 2020-12-31
Free cash flow
-$7.26M
Fiscal year ended 2020-12-31

NextCure, Inc. (NXTC) reported revenue of $0 and net income of -$15.46M for the fiscal year ended 2020-12-31. This page shows 8 annual periods of income statement, balance sheet and cash flow figures normalized from NextCure, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

NextCure, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
Revenue$0$0$0$22.38M$2.00M$1.58M$1.40M$1.36M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$16.24M-$17.40M-$15.80M$8.21M-$12.01M-$9.70M-$8.96M-$6.82M
Net income-$15.46M-$16.37M-$14.51M$9.73M-$10.93M-$8.43M-$8.22M-$6.16M
Research & development$12.11M$12.74M$11.13M$10.58M$11.40M$8.66M$7.64M$6.51M
Weighted-average diluted sharesUnavailableshares 27.55MUnavailableshares 29.35MUnavailableUnavailableUnavailableshares 1.38M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailable$0$0$0Unavailable$0$0$0
Diluted EPSUnavailable$-0.59Unavailable$0.33UnavailableUnavailableUnavailable$-4.46
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$4.13M$4.66M$4.67M$3.59M$2.62M$2.62M$2.71M$1.66M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

NextCure, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
Cash & equivalents$32.77M$22.53M$25.05M$28.91M$34.09M$9.94M$192.69M$125.55M
Total assets$306.64M$316.08M$333.49M$343.47M$356.17M$205.12M$213.05M$145.43M
Current assets$287.98M$296.98M$315.07M$326.66M$340.00M$189.15M$196.52M$131.64M
Total liabilities$12.92M$8.74M$11.57M$11.72M$34.68M$34.48M$34.46M$35.92M
Current liabilities$10.32M$5.74M$8.36M$8.15M$15.04M$12.61M$11.52M$10.30M
Total equity incl. NCI$293.72M$307.34M$321.92M$331.76M$321.48M$170.65M$178.60M-$52.71M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$162.22M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$1.81M$2.22M$2.64M$3.06M$3.33M$3.75M$4.17M$4.72M
Accounts payable$3.90M$186.00K$2.44M$2.26M$1.86M$2.58M$1.99M$2.94M

Cash flow

NextCure, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
Operating cash flow-$6.28M-$15.67M-$12.41M-$10.59M-$9.99M-$7.95M-$10.60M-$7.08M
Capital expenditures$980.00K$1.87M$2.83M$1.44M$814.00K$490.00K$1.13M$935.00K
Investing cash flow$16.50M$13.10M$8.55M$5.37M-$127.16M-$174.70M-$1.13M-$935.00K
Financing cash flow-$398.00K-$363.00K-$414.00K-$240.00K$161.31M-$112.00K$78.88M$2.97M
Net change in cash$9.82M-$2.93M-$4.27M-$5.46M$24.16M-$182.75M$67.14M-$5.04M
Stock-based compensation$2.34M$2.37M$2.19M$1.01M$567.00K$524.00K$412.00K$383.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$977.00K$885.00K$787.00K$751.00K$755.00K$788.00K$582.00K$563.00K

Derived

NextCure, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
Free cash flow-$7.26M-$17.55M-$15.24M-$12.04M-$10.80M-$8.44M-$11.74M-$8.02M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable36.7%-599.0%-612.9%-638.7%-502.2%
FCF marginUnavailableUnavailableUnavailable-53.8%-538.9%-533.0%-837.2%-590.6%
SBC / revenueUnavailableUnavailableUnavailable4.5%28.3%33.1%29.4%28.2%
Current ratio27.89x51.73x37.68x40.07x22.60x15.00x17.05x12.77x
Revenue YoY growth-100.0%-100.0%-100.0%1549.1%UnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailable-545.0%-532.8%UnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable47.3%568.4%547.3%545.1%480.0%
CapEx / revenueUnavailableUnavailableUnavailable6.5%40.6%31.0%80.7%68.9%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NXTC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-05View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-01View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.